课题基金 / 基金详情

Conformation-specific Single-chain Antibodies as Neurodegeneration Research Tools

Conformation-specific Single-chain Antibodies as Neurodegeneration Research Tools
构象特异性单链抗体作为神经变性研究工具
批准号:
7480889
负责人:
ANNE MESSER
金额:
$17.64万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2010-03-31

项目摘要

项目成果

ANNE MESSER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The specific goal of this developmental project is to optimize and characterize conformation-specific single-chain Fv (scFv) antibodies as tools to recognize and manipulate misfolded neurodegeneration proteins intracellularly. We have developed unique capabilities that enable us to generate scFvs that target specific protein morphologies and to test their function intracellularly. Given the known structural commonality of proteins involved in Alzheimer's, Parkinson's, Huntington's, prion, and ALS diseases, these reagents will allow investigators working on these various diseases to distinguish between oligomeric and fibrillar forms of aggregates in a cellular context. It will also allow redirection of specific forms of proteins to other intracellular compartments to test hypotheses of where the most critical site of action resides. This is a multiple-PI application. The anti-alpha-synuclein oligomeric and anti- fibrillar scFvs are currently being selected in the laboratory of Dr. Michael Sierks, at ASU. Much of the first year will be devoted to efficient rapid screening of intracellular expression in neuronal cell lines by Dr. Anne Messer, Wadsworth Center in Albany, NY, followed immediately by the more labor-intensive engineering of affinity and stability of the most promising scFvs. By the second year, the majority of the work will consist of detailed biological studies done in Albany, with further protein interactions and optimization as needed at ASU. PUBLIC HEALTH REVELANCE: Neurodegenerative diseases are taking an increasing human and financial toll as our population ages. Engineered antibody therapeutics are already in use for cancer and infectious disease, and offer an exciting new platform for neurological disease drug discovery and therapeutics. This project specifically targets the consequences of protein misfolding in Parkinson's disease, with direct applications to related diseases such as Alzheimer's, Huntington's, and ALS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Harnessing novel cell-penetrating antibodies for neuronal correction
  • 批准号:
    8263377
  • 项目类别:
  • 资助金额:
    $21.9万
  • 财政年份:
    2011
  • 负责人:
    ANNE MESSER
  • 依托单位:
Harnessing novel cell-penetrating antibodies for neuronal correction
  • 批准号:
    8129300
  • 项目类别:
  • 资助金额:
    $18.3万
  • 财政年份:
    2011
  • 负责人:
    ANNE MESSER
  • 依托单位:
Intrabodies as novel neurological therapeutics
  • 批准号:
    7019240
  • 项目类别:
  • 资助金额:
    $31.46万
  • 财政年份:
    2006
  • 负责人:
    ANNE MESSER
  • 依托单位:
Intrabodies as novel neurological therapeutics
  • 批准号:
    7848421
  • 项目类别:
  • 资助金额:
    $2.55万
  • 财政年份:
    2006
  • 负责人:
    ANNE MESSER
  • 依托单位:
海外基金